As Lester Holt says prior to the closing segment on NBC World News, “There’s good news tonight” – at least in terms of ANDA approval times. In its first quarterly report for FY 2023 all of the approval metrics are under 30 months for the first time that I can remember. (see chart below). This […]
Obviously, we have waited longer for the official monthly statistics in FY 2023 than in previous years. In addition, in prior years, OGD published the approval actions, receipt of new ANDAs and complete response letters prior to releasing the full set of statistics. However, it looks like there will be no early view of these […]
Taking a look at the unofficial approval information on the FDA website through December 16th, we found only twenty‑five ANDAs receiving full‑approval actions and six receiving tentative‑approval actions. That is a total of (obviously) thirty‑one approval actions. Given that number, if the OGD could double its approval output by the end of the month, that would […]
Well, here we are at the conclusion of the second month of FY 2023 and we can still only report unofficial approval numbers. At least we know the reason why (see previous post here), but it’s very important to continue to track these metrics as approvals are the lifeblood of the generic pharmaceutical industry. We […]
The FDA is usually pretty consistent with the timing of their publication of official OGD metrics, especially when it comes to the publication of the Generic Drugs Program Activities Report – Monthly Performance. The first month of official stats has not yet been available and it is almost December. I was curious about the delay, […]
With the end of the 2022 fiscal year, it is always good to take a look back at how the metrics for the year are viewed. While some of the comments in this blog may be mine and mine alone, I think that you all agree with me. If not let me know! We have […]
Well, with the final FY 2022 totals now in for some of the OGD’s most important metrics, let’s see how this fiscal year stacks up other GDUFA years. But first, September saw sixty-eight full-approval actions of which nine were for first-time generics and only nine tentative-approval actions along with ninety-eight new ANDAs and 141 Complete […]
With only the September metrics left to round out the FY 2022 statistical report for the OGD, let’s take a look at the full official numbers for August. We also now have a good idea how FY 2022 will stack up against FY 2021, albeit a lot can happen in a few weeks as we await the […]
With just two months to go in FY 2022, the OGD has updated its July statistical report (here). With the hold‑up on the FY 2023-2027 User Fee legislation, some at the Agency are getting a bit nervous about their job security and firms are scrambling to try to budget for FY 2023 user fee costs; […]
July looks like another good month for OGD approval actions with a reported sixty‑five full‑approval actions and thirteen tentative‑approval actions. In a previous blog post, we reported sixty‑five and twelve in our unofficial counts (here). That darn additional TA was posted after our blog post (so close!). So, the OGD hit over the seventy‑mark again […]